Clinical Report: Smartwatch May Track AD Status in Children

Overview

A prospective study suggests that smartwatch-measured nighttime scratching is moderately associated with disease severity and clinical improvement in pediatric atopic dermatitis. The study involved 50 children aged 4 to 15 years and highlighted the potential of wearable technology as an objective measure of disease activity.

Background

Atopic dermatitis (AD) is a common chronic skin condition in children that significantly impacts quality of life. Monitoring disease severity and treatment response is crucial for effective management. Wearable technology, such as smartwatches, offers a novel approach to objectively assess disease activity through metrics like scratching behavior.

Data Highlights

Key Findings

• Nighttime scratching metrics showed moderate correlations with baseline EASI (0.60 to 0.64).
• Correlations between scratching metrics and clinical improvement were observed (0.67 to 0.71).
• Associations with serum TARC levels were consistent with clinical severity (0.58 to 0.60).
• The SBI-based model distinguished patients achieving clinically meaningful improvement with an AUC of 0.78.
• Weak correlations were noted between numerical rating scale itch scores and clinical measures.

Clinical Implications

Wearable-derived scratching metrics may serve as objective indicators of disease activity in pediatric atopic dermatitis. Clinicians should consider integrating these metrics into routine assessments, while remaining cautious about their current limitations and the need for further validation.

Conclusion

The study indicates that smartwatch technology may provide valuable insights into the management of atopic dermatitis in children, but further research is necessary to confirm its clinical utility.

References

1. American Academy of Dermatology, AAD, 2026 -- American Academy of Dermatology Issues First-Ever Pediatric Atopic Dermatitis Guidelines
2. Fumiko Iwai, Journal of Clinical Medicine, 2023 -- Smartwatch May Track AD Status in Children
3. Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis, ScienceDirect, 2024 -- Dupilumab reduces inflammatory biomarkers
4. Artificial Intelligence-Enabled Wearable Devices and Nocturnal Scratching in Mild Atopic Dermatitis, PubMed, 2023 -- AI-Enabled Wearable Devices
5. retinal physician — Tracking Retinal Health With Wearable Technology
6. The ASCO Post — Are Wearable Physical Activity Monitors Coming of Age in Oncology?
7. The ASCO Post — Are Wearable Physical Activity Monitors Coming of Age in Oncology?
8. Retinal Physician — Tracking Retinal Health With Wearable Technology
9. Tracking Retinal Health With Wearable Technology
10. Are Wearable Physical Activity Monitors Coming of Age in Oncology?
11. American Academy of Dermatology Issues First-Ever Pediatric Atopic Dermatitis Guidelines, Highlighting Prevention Strategies and Effective Treatments
12. Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis - ScienceDirect
13. Artificial Intelligence-Enabled Wearable Devices and Nocturnal Scratching in Mild Atopic Dermatitis - PubMed